Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: J Immunol. 2017 Oct 4;199(10):3504–3515. doi: 10.4049/jimmunol.1700289

Figure 9. AHR antagonist reversed the TCDD-elicited suppression of EBF1 and PAX5 expression.

Figure 9

Human CD34+ HSPCs were treated with vehicle, AHR antagonist CH223191 (CH) (0.3, 1, 3 or 10 μM), TCDD (1 nM) or a combination of CH and TCDD on day 0. Cells were cultured for up to 28 days and harvested at the specified time points. The mRNA levels of EBF1 (A) and PAX5 (B) were determined by real-time quantitative PCR and were normalized to 18s ribosomal RNA. Data are presented as the mean ± SE of triplicate measurements. a = significantly different compared to vehicle control, b = significantly different compared to the TCDD (1 nM) treated group, by two way ANOVA with Bonferroni posttest after logarithmic transformation. Data are representative of two independent experiments with similar results.